3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Carcinoma, Transitional Cell
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Melanoma
2
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Glioblastoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
5
tislelizumab
2
spartalizumab
2
Trastuzumab
2
Psychiatric Rehabilitation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Interleukin-12 Subunit p35
2
Erlotinib Hydrochloride
2
Biopsy
2
trastuzumab deruxtecan
1
tipifarnib
1
regorafenib
1
prexasertib
1
niraparib
1
fludarabine
1
enzalutamide
1
entinostat
1
abiraterone
1
Vorinostat
1
Thalidomide
1
Taxes
1
Surveys and Questionnaires
1
Specimen Handling
1
Ritonavir
1
Radiotherapy
1
Radionuclide Imaging
1
Quality of Life
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anus Neoplasms
×
regorafenib
×
Thoracic
×
Clear all
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn